Skip to main content
OpenTrials
Completed

NCT Number: NCT03790592

Visual Outcomes After Presbyopic Lens Exchange

Evaluation of mean preoperative and postoperative Corrected distance visual acuity (CDVA) after Refractive Lens Exchange in presbyopic patients

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Augenzentrum Michelfeld

Michelfeld, Germany

About this study

Compare preoperative and postoperative Corrected distance visual acuity

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient informed of the consequences and constraints of the protocol and who has given his/her written informed consent
  • Patients of any gender, aged 18 years or older
  • Assured follow-up examinations
  • Post-operative astigmatism ≤ 0.75 Diopter
  • IOL implanted into the capsular bag with trifocal IOL in both eyes
  • Patients who had bilateral uncomplicated presbyopic lens exchange surgery in both healthy eyes
  • Preoperative monocular and binocular CDVA equal or better than 0.2 logMAR
  • Normal findings in the medical history and physical examination

Exclusion criteria

  • Patients unable to meet the limitations of the protocol or likely of non-cooperation during the trial
  • Patients whose freedom is impaired by administrative or legal order
  • Concurrent participation in another drug or device investigation that affects patients vision
  • Signs of early cataract in either eye
  • Preoperative monocular and binocular CDVA worse than 0.2 logMAR
  • Clinically significant Posterior capsule opacification (PCO) defined as a CDVA loss of 0.2 logMAR or more in either eye
  • Cataract of any grade
  • Ocular disorders, that could potentially cause future acuity loss to a level of 0.20 logMAR (best-corrected) or worse in either eye
  • Any anterior segment pathology that could significantly affect outcomes (e.g. chronic uveitis, iritis, aniridia, rubeosis iridis, clinically significant anterior membrane dystrophies, poor pupil dilation, etc.)
  • Abnormal corneal findings in either eye (e.g. keratoconus, pellucid marginal degeneration, or irregular astigmatism, clinically significant corneal membrane dystrophies)
  • Any condition in the study eye that could affect IOL stability (e.g. zonular dialysis, evident zonular weakness or dehiscence, etc.)
  • History of any clinically significant retinal pathology or ocular diagnosis (e.g. diabetic retinopathy, ischemic diseases, macular degeneration, retinal detachment, optic neuropathy optic nerv atrophy, amblyopia, strabismus, microphthalmos, aniridia, epiretinal membrane etc.) in the study eyes that could alter or limit final postoperative visual prognosis.
  • Patients, who are unable to fixate for a longer time, e.g. strabismus, nystagmus
  • Patient expected to require retinal laser treatment before 6 month follow-up visit
  • Patient require refractive laser treatment / refractive laser touch-up before 6 month follow up visit
  • Current Systemic or ocular pharmacotherapy that effects patients vision
  • Floppy iris syndrome
  • Monophthalmic patient
  • Previous corneal surgery
  • Previous use of cytotoxic drugs or total body irradiation
  • Dementia
  • Uncontrolled glaucoma or Intraocular pressure (IOP) higher than 24 millimeter of mercury (mmHg) under ocular hypertension treatment
  • Any other pathology or condition presenting, according to the investigator opinion, a risk for the patient

Treatment and study plan

trifocal IOL

Device

intraocular lens

Primary outcomes

  1. Corrected distance visual acuity

    Time frame: 4 to 6 months postop

    preoperative and postoperative Corrected distance visual acuity will be assessed

Sponsors and collaborators

Lead sponsor

Carl Zeiss Meditec AG

Industry

Registry information

Official study title

Visual Outcomes and Patient Satisfaction After Presbyopic Lens Exchange With a Trifocal Intraocular Lens (IOL)

Acronym: RELAX

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Dec 31, 2018
Registry last updated
Jul 16, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.